Adaptive Melphalan Formulations for Specialized Environments

Publication ID: 24-11857677_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Melphalan Formulations for Specialized Environments,” Published Technical Disclosure No. 24-11857677_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857677_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,677.

Summary of the Inventive Concept

This inventive concept discloses novel melphalan formulations and systems tailored for specific, high-stakes environments, such as emergency response, high-security facilities, disaster relief, extreme weather conditions, and remote monitoring.

Background and Problem Solved

The original patent provided stable ready-to-use injectable formulations of melphalan, but it did not address the unique challenges and requirements of specialized environments. This inventive concept addresses these limitations by adapting the melphalan formulation and preparation process to meet the specific demands of these niche markets.

Detailed Description of the Inventive Concept

The new claims encompass a range of specialized melphalan formulations and systems. For emergency response situations, a portable kit with a mixing device designed to withstand extreme temperatures and humidity conditions is provided. In high-security facilities, a tamper-evident container and monitoring system ensure the integrity of the formulation. For disaster relief situations, a method for reconstituting a lyophilized melphalan powder with a sterile solvent and filtering the resulting solution through a sterilizing filter is disclosed. In extreme weather conditions, an antifreeze agent and protective container are incorporated. Finally, a system for remote monitoring of the melphalan formulation, comprising a sensor, communication device, and software program, ensures the stability and safety of the formulation.

Novelty and Inventive Step

The novelty of this inventive concept lies in the adaptation of the melphalan formulation and preparation process to meet the specific demands of specialized environments, which is non-obvious compared to the original patent. The inventive step is the recognition of the need for tailored solutions in these niche markets and the development of corresponding formulations and systems.

Alternative Embodiments and Variations

Alternative embodiments could include variations in the solvent system, container design, and monitoring technology. For example, the use of alternative antifreeze agents or the incorporation of additional sensors for monitoring other parameters could be explored.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in various industries, including emergency response, high-security facilities, disaster relief, and extreme weather conditions. The market demand for specialized melphalan formulations and systems is substantial, and this inventive concept is well-positioned to capture a significant share of this market.

CPC Classifications

SectionClassGroup
A A61 A61K9/08
A A61 A61K9/0019
A A61 A61K31/198
A A61 A61K47/10
A A61 A61K47/183
A A61 A61K47/32

Field of Art

Pharmaceutical formulations, specifically injectable drug preparations with a focus on stability, preparation methods, and specialized delivery systems for chemotherapeutic agents

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in drug stability, parenteral preparation techniques, specialized packaging, and environmental adaptation strategies, typically holding a PhD or equivalent industrial experience in pharmaceutical sciences

Obviousness Rationale

A PHOSITA would recognize that the specialized melphalan formulation variations represent predictable extensions of the source patent's core teachings about injectable drug stability and preparation. The disclosed environmental adaptations leverage standard pharmaceutical engineering techniques like tamper-evident packaging, sterilization methods, and monitoring systems that are well-established in the field. These variations represent routine problem-solving approaches for adapting pharmaceutical formulations to specific use contexts.

Obvious Combinations & Variations

Source Patent Element
Stable liquid parenteral formulation with defined melphalan concentration and solvent system
PTD Variation
Emergency response portable kit with mixing device for extreme temperature and humidity conditions
Obviousness Reasoning
A PHOSITA would find it obvious to design a portable mixing system that maintains the fundamental formulation stability principles already established in the source patent, using known engineering techniques for environmental protection
Source Patent Element
Pharmaceutically acceptable solvents including propylene glycol and water
PTD Variation
Antifreeze agent incorporated into solvent system for extreme weather conditions
Obviousness Reasoning
Modifying solvent composition to enhance temperature stability is a predictable solution using known pharmaceutical formulation techniques, representing a standard design choice for environmental adaptation
Source Patent Element
Injectable liquid pharmaceutical formulation with focus on stability
PTD Variation
Tamper-evident container and monitoring system for high-security facilities
Obviousness Reasoning
Implementing additional security and monitoring features represents a routine engineering enhancement that a PHOSITA would find obvious when adapting pharmaceutical formulations for specialized environments
Source Patent Element
Parenteral formulation preparation methods
PTD Variation
Lyophilized powder reconstitution method with sterilizing filtration for disaster relief
Obviousness Reasoning
Using lyophilization and sterilizing filtration are standard pharmaceutical techniques for enhancing drug stability and ensuring sterility, which a PHOSITA would readily apply in challenging environmental contexts
Source Patent Element
Liquid pharmaceutical formulation with defined composition
PTD Variation
Remote monitoring system with sensors and communication devices
Obviousness Reasoning
Integrating sensor technology and remote monitoring represents a predictable technological enhancement using standard IoT and pharmaceutical tracking methodologies
35 U.S.C. § 103 Summary: Based on US Patent 11857677's teachings regarding melphalan formulation stability, the present publication demonstrates that the claimed variations represent obvious extensions of known pharmaceutical engineering principles, rendering subsequent claims involving similar environmental adaptations and monitoring strategies unpatentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,677
TitleReady to use injectable formulations of melphalan and processes for preparation thereof
Assignee(s)RK PHARMA INC.